Thursday, November 12, 2026

Abaxx Exchange Posts Record June Volumes Amid Viceroy Short-Seller Attack

Singapore-based Abaxx Exchange reported its highest-ever June trading volumes across every metric, even as it fights a short-and-distort report from Viceroy Research. The company hired Paul Weiss to investigate the claims and alerted regulators in Singapore and Canada.

LM Salvado
LM Salvado

July 9, 2026

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
Abaxx Exchange Posts Record June Volumes Amid Viceroy Short-Seller Attack
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Abaxx Exchange posted record June 2026 trading volumes across every metric it tracks, even as it fights off a short-seller attack.1 Viceroy Research published a report alleging misconduct at Abaxx Technologies, prompting an immediate multi-front response.1

Abaxx retained law firm Paul Weiss to investigate the allegations independently.1 The company also contacted two regulators directly: Singapore's Monetary Authority of Singapore (MAS) and Canada's Investment Regulatory Organization of Canada (CIRO).1

The dual-jurisdiction response reflects Abaxx's structure: a commodities exchange headquartered in Singapore, listed in Canada, serving traders worldwide. Short-and-distort campaigns — pairing a short bet with public allegations to push a stock down — are a recurring test for exchanges and infrastructure firms in any market, from Wirecard in Germany to Adani Group in India.

Abaxx chose to respond quickly rather than stay silent, issuing a public rebuttal disputing Viceroy's claims.1 Reaching out to regulators before they open formal inquiries lets the company shape the narrative on its own terms, a move boards worldwide increasingly favor when governance allegations surface.

The company is leaning on trading data as its strongest counter-argument.1 June volumes beat May's across the board, a signal Abaxx says undercuts claims that would normally spook market participants.1 For an exchange, that distinction matters: infrastructure providers depend on trust in the venue itself, not just growth metrics, since global counterparties route capital through the platform daily.

Market sentiment remains mixed but improving, as traders weigh Viceroy's allegations against Abaxx's rebuttal and volume figures.1 Neither Paul Weiss's investigation nor MAS and CIRO have issued public findings yet.1 Until they do, the dispute leaves international investors balancing documented trading strength against unresolved governance questions — a familiar tension for any exchange operating across multiple regulatory regimes.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
  1. [1]Press releaseGlobeNewswire· June 22, 2026
    Abaxx Continues to Provide Facts Refuting Ongoing Misinformation and Reaffirms Strong Business Fundamentals
  2. [2]Press releaseGlobeNewswire· June 30, 2026
    Raytech Holding Limited Announces Closing of Approximately $6.2 Million Registered Direct Offering of its Ordinary Shares
LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com